FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Chen, Yanhui ^a,b   Zhang, Henghui ^a,b   Liao, Weijia ^c   Zhou, Jinxue ^d   He, Gaixia ^a,b   Xie, Xingwang ^a,b   Fei, Ran ^a,b   Qin, Liling ^c   Wei, Lai ^a,b   Chen, Hongsong ^a,b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases   (China)

^c GUILIN MEDICAL UNIVERSITY   (China)

^d Henan Tumor Hospital   (China)

Author keywords

Carcinoma; Chronic; FOXP3; Gene polymorphism; Hepatitis B; Hepatocellular

Indexed keywords

CYSTEINE; THREONINE; TRANSCRIPTION FACTOR FOXP3;

ADULT; ALLELE; ARTICLE; CANCER GENETICS; CANCER PATIENT; CANCER RECURRENCE; CHINA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR THROMBUS;

ADULT; AGED; ALLELES; CARCINOMA, HEPATOCELLULAR; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATITIS B; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84878707830     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-39     Document Type: Article

References (24)

1. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
2. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Schreiber RD, Old LJ, Smyth MJ, Science 2011 331 1565 1570 10.1126/science.1203486 21436444
3. Bacteria-triggered CD4(+) T regulatory cells suppress Helicobacter hepaticus-induced colitis. Kullberg MC, Jankovic D, Gorelick PL, Caspar P, Letterio JJ, Cheever AW, Sher A, J Exp Med 2002 196 505 515 10.1084/jem.20020556 12186842
4. Relationship of CD4 + CD25+ regulatory T cells to immune status in HIV-infected patients. Tsunemi S, Iwasaki T, Imado T, Higasa S, Kakishita E, Shirasaka T, Sano H, AIDS 2005 19 879 886 10.1097/01.aids.0000171401.23243.56 15905668 (Pubitemid 40834930)
5. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF, J Virol 2004 78 2454 2459 10.1128/JVI.78.5.2454- 2459.2004 14963140 (Pubitemid 38228938)
6. Circulating and liver resident CD4 + CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z, Zhao JM, Zhang B, Shi M, Ding X, et al. J Immunol 2006 177 739 747 16785573 (Pubitemid 43939189)
7. Control of regulatory T cell development by the transcription factor Foxp3. Hori S, Nomura T, Sakaguchi S, Science 2003 299 1057 1061 10.1126/science.1079490 12522256 (Pubitemid 36222930)
8. Foxp3 programs the development and function of CD4 + CD25+ regulatory T cells. Fontenot JD, Gavin MA, Rudensky AY, Nat Immunol 2003 4 330 336 12612578 (Pubitemid 36432314)
9. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Nat Med 2004 10 942 949 10.1038/nm1093 15322536 (Pubitemid 39273735)
10. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW, Cancer Immunol Immunother 2009 58 449 459 10.1007/s00262-008-0583-5 18791714
11. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH, J Clin Oncol 2006 24 5373 5380 10.1200/JCO.2006.05.9584 17135638 (Pubitemid 46623168)
12. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang H, Zhang H, Zhou C, et al. Gastroenterology 2007 132 2328 2339 10.1053/j.gastro.2007.03.102 17570208 (Pubitemid 46890865)
13. Regulatory T cells, tumour immunity and immunotherapy. Zou W, Nat Rev Immunol 2006 6 295 307 10.1038/nri1806 16557261
14. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B, Fumoleau P, Ghiringhelli F, Clin Cancer Res 2008 14 2413 2420 10.1158/1078-0432.CCR-07-4491 18413832 (Pubitemid 351551075)
15. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grussel S, Sipos B, Grutzmann R, Pilarsky C, Ungefroren H, Saeger HD, et al. Cancer Res 2007 67 8344 8350 10.1158/0008-5472.CAN-06-3304 17804750 (Pubitemid 47395173)
16. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Ebert LM, Tan BS, Browning J, Svobodova S, Russell SE, Kirkpatrick N, Gedye C, Moss D, Ng SP, MacGregor D, et al. Cancer Res 2008 68 3001 3009 10.1158/0008-5472.CAN-07-5664 18413770 (Pubitemid 351556301)
17. Foxp3 expression in human cancer cells. Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, Kerenidi T, Barda AK, Gourgoulianis KI, Germenis AE, J Transl Med 2008 6 19 10.1186/1479-5876-6-19 18430198 (Pubitemid 351712556)
18. The rs3761548 polymorphism of FOXP3 is a protective genetic factor against allergic rhinitis in the Hungarian female population. Fodor E, Garaczi E, Polyanka H, Koreck A, Kemeny L, Szell M, Hum Immunol 2011 72 926 929 10.1016/j.humimm.2011.06.011 21763379
19. Analysis of FOXP3 polymorphisms in infertile women with and without endometriosis. Andre GM, Barbosa CP, Teles JS, Vilarino FL, Christofolini DM, Bianco B, Fertil Steril 2011 95 2223 2227 10.1016/j.fertnstert.2011.03.033 21481380
20. Chronic hepatitis B: update 2009. Lok AS, McMahon BJ, Hepatology 2009 50 661 662 10.1002/hep.23190 19714720
21. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, Vatan L, Finlayson E, Huang E, Simeone D, et al. Cancer Res 2009 69 3995 4000 10.1158/0008-5472.CAN-08-3804 19383912
22. Role of forkhead box protein 3 expression in invasive breast cancer. Wolf AM, Rumpold H, Wolf D, Gastl G, Reimer D, Jenewein N, Marth C, Zeimet AG, J Clin Oncol 2007 25 4499 4500 10.1200/JCO.2007.13.2092 17906214 (Pubitemid 350013859)
23. FOXP3 expression and overall survival in breast cancer. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S, Tagliabue E, Balsari A, J Clin Oncol 2009 27 1746 1752 10.1200/JCO.2008.17.9036 19255331
24. Cyclooxygenase-2 gene promoter polymorphisms affect susceptibility to hepatitis C virus infection and disease progression. Sakaki M, Makino R, Hiroishi K, Ueda K, Eguchi J, Hiraide A, Doi H, Omori R, Imawari M, Hepatol Res 2010 40 1219 1226 10.1111/j.1872-034X.2010.00727.x 20880066